Eslicarbazepine Acetate: A Review in Focal-Onset Seizures
- PDF / 967,903 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 29 Downloads / 188 Views
ADIS DRUG EVALUATION
Eslicarbazepine Acetate: A Review in Focal‑Onset Seizures Young‑A Heo1
© Springer Nature Switzerland AG 2020
Abstract Eslicarbazepine acetate (Zebinix®), a voltage-gated sodium channel blocker, is a once-daily, orally administered anti-seizure medication available in the EU for use as monotherapy in adults with newly diagnosed focal-onset seizures and as adjunctive therapy in adults, adolescents and children aged > 6 years with focal-onset seizures. In adult patients, adjunctive eslicarbazepine acetate was generally associated with a significant decrease in seizure frequency and an increase in responder rate compared with placebo. The drug was also an effective monotherapy agent in adult patients, demonstrating noninferiority to controlled-release carbamazepine, in terms of seizure freedom rates. In paediatric patients, eslicarbazepine acetate provided seizure control when administered as adjunctive therapy, with the benefits appearing to be dependent on age and dose. The antiepileptic efficacy of eslicarbazepine acetate as adjunctive therapy or as monotherapy was maintained during longer-term extension studies, with each extension study period being up to 2 years. Oral eslicarbazepine acetate was generally well tolerated when administered as adjunctive therapy or monotherapy in adult patients and when administered as adjunctive therapy in paediatric patients, with most adverse events being of mild or moderate intensity. In conclusion, with the convenience of once-daily administration, eslicarbazepine acetate is an effective and generally well-tolerated treatment option for adults, adolescents and children aged > 6 years with focal-onset seizures.
1 Introduction Epilepsy is one of the most common neurological diseases, affecting ≈ 70 million people worldwide, with focal-onset seizures (previously known as partial-onset seizures [1]) being the most frequent seizure type in patients with epilepsy [2]. Anti-seizure medications (ASMs) are the mainstay of epilepsy treatment, with the goal being achieving seizure control whilst minimizing adverse events (AEs) associated with ASMs [3]. However, despite a substantial increase in The manuscript was reviewed by: D. Lindhout, Department of Genetics, University Medical Center Utrecht/Stichting Epilepsie Instellingen Nederland, Heemstede, the Netherlands; E. Santamarina, Epilepsy Unit, Neurology Department, Hospital Vall d´Hebron, Barcelona, Spain; P.E. Smith, Welsh Epilepsy Centre, University Hospital of Wales, Cardiff, United Kingdom; A. Strzelczyk, Department of Neurology and Epilepsy Center Frankfurt Rhine-Main, Goethe-University Frankfurt and University Hospital Frankfurt, Frankfurt, Germany. Enhanced material for this Adis Drug Evaluation can be found at https://doi.org/10.6084/m9.figshare.12486323. * Young‑A Heo [email protected] 1
Springer, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand
Eslicarbazepine acetate: clinical considerations in focal‑onset seizures A once-daily, orally administered voltage-gated sodium channel
Data Loading...
